Latest Updates of Viva Biotech's Portfolio Companies

News

}

Home / News / Portfolio Highlights / Portfolio Highlights detail

Time: 2025-09-02

Source: Viva Biotech

[Abstract]:Recently, 2 of Viva's portfolio companies have achieved significant results and progress.

Recently, Viva Biotech's portfolio companies have new updates: Arthrosi and AceLink made solid progress in R&D.

Arthrosi Therapeutics Achieves Full Enrollment of the Second Pivotal Phase 3 Trial of Pozdeutinurad (AR882) in Patients with Gout, Including Those with Tophaceous Gout

SAN DIEGO, Aug. 20, 2025 — Arthrosi Therapeutics, Inc., invested by Viva BioInnovator (VBI), a late-stage biotechnology company advancing a potentially best-in-class, highly potent and selective next generation URAT1 inhibitor to reduce serum urate (sUA) levels, flares, and dissolve tophi in gout and tophaceous gout patients, announced the completion of patient enrollment in its second pivotal global Phase 3 trial, REDUCE 1, evaluating pozdeutinurad (formerly AR882) for the reduction of sUA and tophi in gout and tophaceous gout patients.

AceLink Therapeutics Completes 6-Month Primary Phase of AL01211 Clinical Study in Fabry Disease Patients

NEWARK, Calif. — AceLink Therapeutics, invested and incubated by Viva BioInnovator (VBI), a clinical-stage biopharmaceutical company developing best-in-class substrate reduction therapies for lysosomal storage disorders, announced the successful completion of the 6-month primary treatment phase of its ongoing Phase 2 study of AL01211 (a novel oral GCS inhibitor) in treatment-naive male patients with classic Fabry disease, with the drug demonstrating favorable safety and robust biomarker reduction.

About Arthrosi
Arthrosi Therapeutics, Inc., headquartered in San Diego, CA, is focused on developing pozdeutinurad (AR882), a potentially best-in-class, highly potent and selective next generation URAT1 inhibitor to reduce serum urate levels, flares and tophi in patients with gout. Pozdeutinurad has demonstrated encouraging efficacy and safety compared to SOC in Phase 2 studies as well as impressive results in achieving complete resolution of tophi in a Phase 2b study. Arthrosi is currently advancing pozdeutinurad in a pivotal Phase 3 program.

About AceLink
AceLink Therapeutics is a clinical-stage biopharmaceutical company developing next-generation substrate reduction therapies for lysosomal storage disorders. The company combines deep expertise in glycosphingolipid metabolism with a focus on patient-centric drug design to deliver safe, effective, and accessible treatments for rare diseases.

Previous Page：None... Next Page：Arthrosi Therapeutics Achieves Full Enrollment of the Second Pivotal Phase 3 Trial of Pozdeutinurad (AR882) in Patients with Gout, Including Those with Tophaceous Gout

Back

Media contact: vivapr@vivabiotech.com